Vmn1r39 Inhibitors
Vmn1r39, a member of the vomeronasal receptor family, plays a pivotal role in the complex system of pheromone detection and subsequent modulation of social and reproductive behaviors. Positioned within the vomeronasal organ, Vmn1r39 is intricately involved in signal transduction pathways critical for interpreting chemical cues in the environment, specifically pheromones emitted by conspecifics. The gene encodes a receptor protein that, upon activation by pheromones, initiates cascades of intracellular events leading to neuronal signals and, ultimately, behavioral responses. Vmn1r39's function extends beyond mere chemosensory reception, influencing the intricate tapestry of social interactions and reproductive behaviors in various species.
Understanding the molecular mechanisms underlying the inhibition of Vmn1r39 sheds light on potential regulatory strategies within the cellular milieu. Various inhibitors, spanning different classes of chemicals, exert their influence on Vmn1r39 either directly or indirectly. Direct inhibitors often disrupt specific cellular processes crucial for proper receptor functioning. For instance, inhibitors of vesicle trafficking, like Brefeldin A, impede the proper localization of Vmn1r39, disrupting its signaling capability. Indirect inhibitors, on the other hand, target broader cellular pathways intersecting with those involved in Vmn1r39 regulation. Compounds such as SB-431542 and LY294002 inhibit the TGF-β and PI3K-Akt pathways, respectively, leading to downstream alterations that impact Vmn1r39 expression. These indirect modulations reveal the intricate interconnectedness of cellular pathways in orchestrating the regulation of this key vomeronasal receptor. The exploration of diverse chemical inhibitors not only provides insights into potential avenues for manipulating Vmn1r39 activity but also contributes to a deeper understanding of the intricate signaling networks that govern pheromone-mediated behaviors across species.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts vesicle trafficking by inhibiting ADP-ribosylation factors (ARFs). This interference prevents proper localization of Vmn1r39, impeding its function in signal transduction within the vomeronasal organ. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542, a selective inhibitor of TGF-β type I receptor, indirectly hampers Vmn1r39 expression by obstructing the TGF-β signaling pathway. This disruption influences downstream elements affecting gene transcription related to Vmn1r39 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 acts as a MEK inhibitor, targeting the MAPK pathway. By disrupting this pathway, it indirectly impacts Vmn1r39, as its signaling cascades intersect with the MAPK pathway, altering downstream processes crucial for proper Vmn1r39 functioning. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K-Akt pathway. This interference indirectly affects Vmn1r39 by modulating downstream targets of the PI3K pathway, leading to alterations in the cellular processes involved in Vmn1r39 expression and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, impacting the PI3K-Akt pathway. Through this modulation, Vmn1r39 undergoes indirect inhibition, as downstream elements of the PI3K pathway play a pivotal role in the regulation of Vmn1r39 expression and related cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, an inhibitor of MEK1/2, disrupts the MAPK pathway. This interference indirectly influences Vmn1r39, as the MAPK pathway intersects with the signaling cascades involved in Vmn1r39 expression and function, leading to alterations in its cellular processes. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
LY2109761, a TGF-β receptor inhibitor, indirectly hampers Vmn1r39 by disrupting the TGF-β signaling pathway. This interference leads to alterations in downstream elements crucial for the regulation of Vmn1r39 expression and its related cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, impacting the JNK signaling pathway. Through this modulation, Vmn1r39 undergoes indirect inhibition, as the JNK pathway intersects with signaling cascades regulating Vmn1r39 expression and related cellular processes. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $194.00 $464.00 | 6 | |
LY411575, a γ-secretase inhibitor, indirectly influences Vmn1r39 by disrupting the Notch signaling pathway. This interference alters downstream targets crucial for Vmn1r39 expression and function, leading to modifications in the cellular processes involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 202190, a p38 MAPK inhibitor, disrupts the p38 MAPK pathway. This interference indirectly impacts Vmn1r39, as the p38 MAPK pathway intersects with signaling cascades involved in the regulation of Vmn1r39 expression and related cellular processes. | ||||||